GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [PSA] STEP is not what most of this community thinks it is — 27 comments in the full submission. View in context.
643
c/trialwatch·submitted 1 year ago by u/adaeze_weiss

[PSA] STEP is not what most of this community thinks it is

Readoutbranch of 6 comments

STEP is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence. Quoted a figure here confidently, got asked whether it was ITT, went and…

Read the full submission and all 27 comments →

This branch

6 comments, started 1 year ago
u/trialwatch_theoMOD31 points·1 year ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/bastian_ekstrom11 points·1 year ago

SELECT was cardiovascular outcomes, not weight

replysharereportpermalink
u/iman_castellanos16 points·1 year ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/rohan_steiner8 points·1 year ago

Push back: an open-label extension tells you about the people who stayed.

This is the distinction that would end about half the arguments on this board.

replysharereportpermalink
u/adaeze_weissOP3 points·1 year ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.